458 Studies Now Enrolling
FDI 79: A MULTICENTER PROSPECTIVE STUDY OF CA 125 AND HE4 SERUM BIOMARKERS FOR MONITORING THE RESPONSE TO FIRST-LINE THERAPY IN WOMEN WITH PRIMARY EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCERS EXCLUDING OVARIAN TUMORS OF LOW MALIGNANT POTENTIAL
Study of CA 125 and HE4 Serum Biomarkers in Women with Ovarian, Fallopian Tube, or Primary Peritoneal Cancers (Excluding Ovarian Tumors)
| Sponsor: | Fujirebio Diagnostics, Inc. |
| Enrolling: | Female Patients Only |
| IRB Number: | AAAN4308 |
| Contact: | Reena Vattakalam: 212-342-6895 / rmv2110@cumc.columbia.edu |
Additional Study Information:
HE4 (Human Epididymis Protein 4) is a biomarker expressed in the normal lining of the female genital tract and breast. We are doing this research study to if HE4 is an indicator of treatment response during initial therapy for Primary Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancers. For this we will collect blood at specific intervals. You are being asked to take part in this study because you have been diagnosed with Primary Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer and will be receiving initial treatment for your disease.
This study is closed
Do You Qualify?
| Have you been diagnosed with primary epithelial ovarian, fallopian tube, or primary peritoneal cancer? | Yes | No |
| Chemotherapy prior to primary surgery is permitted, but you must enroll on study prior to start of treatment. Do you understand? | Yes | No |
| Will you have primary surgery performed at Columbia University? | Yes | No |